Literature DB >> 24549402

Effects of phased joint intervention on IL-35 and IL-17 expression levels in patients with portal hypertension.

Yugang Wang1, Jinbin Dong1, Wenying Meng1, Jiali Ma1, Na Wang1, Jue Wei1, Min Shi1.   

Abstract

The aim of the present study was to investigate the clinical efficacy of phased joint intervention [percutaneous transhepatic variceal embolization (PTVE) + phased partial splenic embolization (PSE)] in patients with portal hypertension complicated by esophageal variceal bleeding and hypersplenism and the effect of this intervention on interleukin-35 (IL-35)/IL-17 expression. A review of 53 patients with portal hypertension caused by liver cirrhosis and complicated by esophageal variceal bleeding and hypersplenism treated with phased joint intervention was conducted, and portal hemodynamics, routine blood examinations and liver function were determined. Quantitative polymerase chain reaction (qPCR) was used to evaluate EBI3, FOXP3 and IL-17 mRNA expression levels in peripheral blood mononuclear cells (PBMC) before and after the phased joint intervention, while western blot analysis was used to determine their protein expression. All 53 patients required emergency hemostasis resulting in an emergency hemostatic rate of 100%. Varicose veins disappeared, portal hemodynamics and liver function improved subsequent to the intervention. The expression levels of EBI3, FOXP3 and IL-17 mRNA in the postoperative group were significantly lower than the preoperative levels (P<0.01). The protein expression levels of EBI3, FOXP3 and IL-17 in the postoperative group were reduced compared with the preoperative levels. The concentrations of IL-35, IL-6 and IL-17 in peripheral blood were significantly reduced after the phased joint intervention (P<0.01). Serum IL-35, IL-6 and IL-17 levels were positively correlated with total bilirubin and international normalized ratio, and negatively correlated with albumin. The phased joint intervention can effectively treat esophageal variceal bleeding and hypersplenism, and improve liver function. The efficacy of this intervention may be associated with the regulation of immune function.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24549402     DOI: 10.3892/ijmm.2014.1662

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  5 in total

1.  Elevated serum IL-35 and increased expression of IL-35-p35 or -EBI3 in CD4(+)CD25(+) T cells in patients with active tuberculosis.

Authors:  Bin Kong; Gan-Bin Liu; Jun-Ai Zhang; Xiao-Xia Fu; Wen-Yu Xiang; Yu-Chi Gao; Yuan-Bin Lu; Xian-Jing Wu; Feng Qiu; Wan-Dang Wang; Lai-Long Yi; Ji-Xin Zhong; Zheng W Chen; Jun-Fa Xu
Journal:  Am J Transl Res       Date:  2016-02-15       Impact factor: 4.060

2.  Effects of phased joint intervention on Rho/ROCK expression levels in patients with portal hypertension.

Authors:  Min Shi; Jue Wei; Wen-Ying Meng; Na Wang; Ting Wang; Yu-Gang Wang
Journal:  Exp Ther Med       Date:  2016-06-14       Impact factor: 2.447

3.  Lower level of IL‑35 and its reduced inhibition in Th17 cells in patients with bone marrow mononuclear cells Coombs test‑positive hemocytopenia.

Authors:  Yi Li; Yihao Wang; Hui Liu; Kai Ding; Shanfeng Hao; Yuanyuan Shao; Honglei Wang; Jin Chen; Lei Huang; Zonghong Shao; Rong Fu
Journal:  Mol Med Rep       Date:  2017-12-11       Impact factor: 2.952

Review 4.  IL-35: a potential therapeutic target for controlling hepatitis B virus infection.

Authors:  Xiao Gang Xiang; Qing Xie
Journal:  J Dig Dis       Date:  2015-01       Impact factor: 2.325

Review 5.  The Role of IL-35 in the Pathophysiological Processes of Liver Disease.

Authors:  Shuang Hu; Pan-Pan Lian; Ying Hu; Xing-Yu Zhu; Shao-Wei Jiang; Qiang Ma; Liang-Yun Li; Jun-Fa Yang; Li Yang; Hai-Yue Guo; Hong Zhou; Chen-Chen Yang; Xiao-Ming Meng; Jun Li; Hai-Wen Li; Tao Xu; Huan Zhou
Journal:  Front Pharmacol       Date:  2021-01-21       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.